Back

Why still talk about implementation of SGLT2 inhibitors?

30 August 2025 (12:35 - 12:48)
Organised by: Logo
Congress Presentation Part of: Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients Chronic Heart Failure Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Biykem Bozkurt

Baylor College of Medicine, Houston (United States of America)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor B. Bozkurt (Houston, US)
Slides
Presentation thumbnail
What are the barriers we need to break?
Professor P. Campbell (Newry, GB)
Presentation thumbnail
How do we identify patients with HFpEF?
Doctor C. Saldarriaga (Medellin, CO)
Presentation thumbnail
What are the wider benefits of SGLT2 inhibitors for cardio-renal-metabolic conditions?
Professor N. Marx (Aachen, DE)
Presentation thumbnail
Close
Professor B. Bozkurt (Houston, US)

Access the full session

Session thumbnail
Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 12:35 CET
You may be interested in
thumbnail
Congress Session
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the outpatient setting
27 August 2023
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Session
No time like the present: heart failure in the hospital setting
30 August 2024
thumbnail
Congress Presentation
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources